RLAYRelay Therapeutics, Inc.
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion After skyrocketing 1,027% off a low, Relay Therapeutics taps AI and machine learning to fuel more gains. | ||
 Relay Therapeutics (RLAY) Reported Q2 Results, Is The Premium P B Multiple Justified? Relay Therapeutics (RLAY) reported second quarter 2026 results, with revenue of US$0.35 million and a net loss of US$83.71 million. This provides investors with fresh data on this clinical stage biotech stock. See our latest analysis for Relay Therapeutics. The earnings release comes after a sharp share price recovery for Relay Therapeutics, with a 90 day share price return of 51.83% and a year to date share price return of 153.55%, while the 1 year total shareholder return is very large at... | ||
 The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci AI is reshaping drug discovery, with Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci advancing computational platforms and pipelines. | ||
 4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma RXRX, SDGR, RLAY and ABSI are using AI-powered platforms to transform drug discovery while advancing proprietary clinical pipelines. | ||
 Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year Relay Therapeutics (RLAY) is a clinical-stage precision medicines company focused on targeted oncology, with a $4.4 billion market cap. RLAY has surged 486% over the past year. Shares are trading near a new 3-year high. Technical momentum is strong, but fundamentals show that revenue is expected to decrease by more... | ||
 Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates Relay Therapeutics (RLAY) delivered earnings and revenue surprises of 0.00% and -86.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of +33.33% and -5.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy? Relay Therapeutics (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. | ||
IInsider Monkey | ||